Milestones and Timeline. Milestone Chart Year Year 1 (etc) Quarter 1 2 3 4 (etc) Specific Aim 1: (add text) Task 1: (add text) Task 2: (add text) (etc)
Milestones and Timeline. Please provide detailed information on the expected steps toward completion, including the various stages of research, drafts, revisions, and final submissions. Tasks to be completed by the student Due Date
Milestones and Timeline. (Please feel free to use format appropriate for your project) Months 1-9 Months 10-18 Months 19-24 Objective 1 ****** *** Milestone 1.1 X Milestone 1.2 X Milestone 1.3 X Objective 2 *** ***** Milestone 2.1 X Milestone 2.2 X Milestone 2.3 X Objective 3 ** Milestone 3.1 X MabVax Therapeutics, Inc. Attachment 1 INVOICE/FINANCING REQUEST AND CONTRACT FINANCIAL REPORTING INSTRUCTIONS FOR NIH COST-REIMBURSEMENT CONTRACTS, NIH(RC)-4 Format: Submit payment requests on the Contractor’s self-generated form in the manner and format prescribed herein and as illustrated in the Sample Invoice/Financing Request. Standard Form 1034, Public Voucher for Purchases and Services Other Than Personal, may be used in lieu of the Contractor’s self-generated form provided it contains all of the information shown on the Sample Invoice/Financing Request. DO NOT include a cover letter with the payment request.
Milestones and Timeline. Please provide detailed information on the expected steps toward completion, including the various stages of research, drafts, revisions, and final submissions. Tasks to be completed by the student Due Date Feedback and Revisions: Please explain who will provide feedback to the student and with what frequency. If a committee will provide feedback and review of student progress, please explain what the student should expect of this process.
Milestones and Timeline. Phase 2 clinical trial will be initiated for castrate resistant prostate cancer patients – based on the results of IND134672. The new trial will be executed combining an androgen signaling inhibitor (e.g. abiraterone [Zytiga; Jxxxxxx]) with ENV105. This involves obtaining FDA approval for the ENV105 Phase 2 trial following regulatory approval by Cedars-Sinai Medical Center. - Study biomarkers for ENV105 - Develop Phase 1 clinical trial for ENV105 combination with external beam irradiation for localized ER+ breast cancer. Enviro Therapeutics Inc. Development Plan ENV105 will be aggressively pursued in pre-clinical and clinical trials. Future therapeutic targets will be developed based on the overriding mission to complement traditional cancer-targeted drugs with those that address the tumor microenvironment. Enviro Therapeutics will strive to co-develop companion biomarkers with all drugs in its portfolio.
Milestones and Timeline. Produce ENV205 for preclinical testing. - Demonstrate ENV205 efficacy in synergizing with docetaxel in breast cancer mouse models. - Measure changes in cognitive impairment and cardiac toxicity with ENV205. - Study biomarkers for ENV205 - Develop Phase 1 clinical trial for ENV205 combination with paclitaxel for metastatic breast and prostate cancer. Enviro Therapeutics Inc. Development Plan ENV205 will be aggressively pursued in pre-clinical and clinical trials. Future therapeutic targets will be developed based on the overriding mission to complement traditional cancer-targeted drugs with those that address the tumor microenvironment. Enviro Therapeutics will strive to co-develop companion biomarkers with all drugs in its portfolio. Preclinical Plan: - Year 1: Produce ENV205 for preclinical testing. Demonstrate ENV205 efficacy in synergizing with docetaxel in breast cancer mouse models. - Year 2: Measure changes in cognitive impairment and cardiac toxicity with ENV205. - Year 2: And identify other cancer targets for ENV205 - Year 2: Study biomarkers for ENV205 Clinical Plan: - Year 3: Develop Phase 1 clinical trial for ENV201 combination with paclitaxel for metastatic breast and prostate cancer. Schedule D
Milestones and Timeline. Provide a summary of expected results for each objective, and an overall timeline for accomplishing all objectives and specific aims. Potential Problems and Anticipated Solutions Cite factors which might negatively impact the work and how any potential risks will be mitigated.
Milestones and Timeline. Grantee shall use its reasonable best efforts to complete the activities set forth in the Proposal. Grantee shall notify Grantor immediately, in writing, of any event that reduces or is likely to materially reduce Grantee’s ability to undertake the activities set forth in the Proposal. Material changes in the Proposal require the advance written approval of Grantor.
Milestones and Timeline. The major milestones and timeline shall be subject to variation in the event of any of the following:
Milestones and Timeline. Grantee shall use Commercially Reasonable Efforts to achieve the milestones and timeline (“Milestones and Timeline”) set forth in Exhibit A. Material changes in the Milestones and Timeline require the advance written approval of Grantor. In performing the activities set forth in the Milestones and Timeline, Grantee shall comply with all relevant federal, state, or local laws and regulations, and executive orders applicable to such activities. Without limiting the preceding sentence, Grantee shall comply with all federal and state laws relating to discrimination by employers or in public accommodations, receipt and disbursement of state and federal funds, tax reporting and withholding requirements, workers’ compensation, and wage and hour laws, in each case as they relate to Grantee’s activities to meet the Milestones and Timeline.
